500013-42-3

Basic information

• Product Name: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE
• Synonyms: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE;benzyl 4-(2-(tert-butoxycarbonyl)aminoethyl)piperazine-1-carboxylate
• CAS NO: 500013-42-3
• Molecular Formula: C₁₉H₂₉N₃O₄
• Molecular Weight: 363.45
• Mol File: 500013-42-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE(500013-42-3)
• EPA Substance Registry System: 1-CBZ-4-(2-N-BOC-AMINO-ETHYL)-PIPERAZINE(500013-42-3)

Safety Data

• Hazardous Substances Data: 500013-42-3(Hazardous Substances Data)

Usage

Type of Compound

Piperazine derivative

Functional Groups

Carbobenzyloxy (CBZ) and tert-butyloxycarbonyl (BOC) protecting groups

Purpose

Used in organic synthesis and pharmaceutical research

Application

Intermediate in the synthesis of various pharmaceuticals and bioactive molecules

Usage

Development of potential drug candidates

Additional Applications

Production of peptides, peptidomimetics, and other organic compounds

Protecting Groups

Prevent unwanted side reactions during chemical reactions

Nitrogen Atom

CBZ protecting group attached

Amino Group

BOC protecting group attached

Upstream product

• 500013-41-2 benzyl 4-(2-bromoethyl)piperazine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 140-31-8 aminoethylpiperazine 
• 501-53-1 benzyl chloroformate 
• 100450-84-8 N-[phenylmethylidene]-2-piperazin-1-ylethanamine 
• 104740-55-8 4-(2-aminoethyl)-1-piperazinecarboxylic acid phenylmethyl ester 

Downstream Products

• 1710768-30-1 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral gp120 receptor (e.g., temsavir, BMS-818251, DMJ-ll-121, BNM-IV-147, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin- binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., HIV infections).

Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: A comparative study

Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) and has been approved for the treatment of haematological malignancies, such as chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenstr?m's macroglobulinemia. The covalent and irreversible nature of its molecular mode of action allows identification and monitoring of its target in an activity-based protein profiling (ABPP) setting. Fluorescent and biotinylated ibrutinib derivatives have appeared in the literature in recent years to monitor BTK in vitro and in situ. The work described here complements this existing methodology and pertains a comparative study on the efficacy of direct and two-step bioorthogonal ABPP of BTK.